Egalet CEO: 'We are moving the company closer and closer to profitability'
Egalet executives believe their company — which received a “going concern” warning from its auditors earlier this month — is headed in the right direction.
Robert Radie, CEO of the Wayne specialty pharmaceutical company that specializes in abuse deterrent pain medicines, said Egalet’s net revenues climbed 55 percent to $26.1 mi llion last year. It also took steps to curtail spending this year be between $20 million and $25 million.
“We are excited about the business we are building,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news